JNJ-67953964
Sponsors
Janssen Cilag International, Janssen Research & Development, LLC, Janssen Pharmaceutical K.K.
Conditions
Depressive Disorder, MajorHealthyMajor Depressive DisorderMajor Depressive Disorder (MDD) with Moderate-to-severe Anhedonia
Phase 1
A Study to Investigate the Effect of JNJ-67953964 on Gastric Mucosal Integrity in Healthy Male and Female Participants
CompletedNCT04185051
Start: 2019-12-17End: 2021-05-05Updated: 2025-04-27
A Study of JNJ-67953964 in Healthy Japanese Adult Male Participants
CompletedNCT04791332
Start: 2021-04-30End: 2021-07-28Updated: 2025-04-28
Phase 2
Phase 3
An Open-label, Long-term, Safety and Efficacy Study of Aticaprant as Adjunctive Therapy in Adult and Elderly Participants With Major Depressive Disorder (MDD)
CompletedCTIS2023-508163-74-00
Start: 2023-06-12End: 2025-02-28Target: 356Updated: 2024-11-11
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open-label Long-term Extension Treatment with Aticaprant
CompletedCTIS2024-511557-21-00
Start: 2024-11-14End: 2025-02-28Target: 212Updated: 2024-11-06
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia
CompletedCTIS2024-511057-22-00
Start: 2024-12-04End: 2025-02-28Target: 339Updated: 2024-12-12